StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
UPDATE: Allergan (AGN) Pressured After U.S. Treasury, IRS Seek to Reduce Benefits of Inversions
April 4, 2016 5:24 PM
(Updated - April 4, 2016 5:26 PM EDT)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Litigation
Mergers and Acquisitions
Trader Talk
Next Articles
Leerink Partners Cuts Price Target on Allergan (AGN) Following New U.S. Treasury Regulations
April 6, 2016 7:13 AM
Buy Allergen (AGN) at $220 Regardless of Deal Outcome - Leerink
April 5, 2016 8:54 AM
Allergen (AGN) Trading Below Standalone Value Following New Treasury Action - RBC
April 5, 2016 6:42 AM
Allergan (AGN), Pfizer (PFE) Comment on U.S. Treasury Action; Won't Comment on Potential Impact
April 5, 2016 6:37 AM
U.S. Treasury Announces Latest Action to Limit Corporate Inversions
April 4, 2016 5:04 PM
U.S. Treasury, IRS issue more curbs to corporate tax inversion deals
April 4, 2016 5:01 PM
